YIDU TECH (02158) has recently demonstrated strong business development momentum. Following a recent announcement of winning a bid for the Artificial Intelligence Construction Bank-Hospital Cooperation Project at Peking University Cancer Hospital, valued at approximately 4.88 million yuan, the company has now announced another successful bid. It has secured the Hainan Province Integrated Regional Infectious Disease Surveillance, Early Warning, and Emergency Command Information Platform (Phase II) project with a contract value of nearly 12.89 million yuan. These two contract wins are viewed as dual breakthroughs for the company in the commercialization of its large medical AI model and in the field of intelligent public health.
The project with Peking University Cancer Hospital is interpreted by the market as a key milestone for the deployment of YIDU TECH's large medical AI model. This collaboration will use a top-tier specialized oncology institution in China as a benchmark scenario, providing a foundation for demonstrating the scalable expansion of the large medical model within specialized clinical pathways. The Hainan public health project further solidifies the company's capabilities in providing digital public health services to government clients, creating a dual-drive structure encompassing both "hospital-side" and "public health-side" operations.
Recently, on April 9th, YIDU TECH held a specialized investor exchange meeting titled "Yidu Zhi Xun," which attracted nearly a hundred representatives from well-known domestic and international funds and major brokerage firms. The clinical evidence-based intelligent agent "Yidu Zhi Xun," which was a key focus of the presentation, received high recognition from investors due to its deep understanding of clinical workflows and its potential for new business models.
Based on these positive developments, Citigroup recently issued a research report reiterating its "Buy" rating on YIDU TECH and setting a target price of HK$11.00. Citigroup believes the launch of "Yidu Zhi Xun" is expected to deepen the company's connection with the physician community, strengthen its Big Data Platform and Solutions (BDPS) business within hospital networks, and open up a new token-based payment model. The report specifically highlighted that, compared to similar products launched by internet companies, YIDU TECH's core advantage lies in its deep integration with internal hospital medical data and a more profound understanding of clinical scenarios.
The consecutive wins of significant projects and positive institutional ratings indicate dual progress for YIDU TECH in both technology commercialization and building market trust. Analysts suggest that with the promotion of innovative products like "Yidu Zhi Xun," the company is well-positioned to evolve in the medical AI sector from a project-based model towards a more sustainable, usage-based service model.
Comments